Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

on in managing their cholesterol levels.

"There is a lot of interest in PCSK9 as an exciting new target for the treatment of high cholesterol and having demonstrated that SPC5001 effectively lowers LDL or the 'bad' cholesterol in preclinical studies, we are quickly moving forward with plans to advance SPC5001 into clinical studies as a potential new treatment to help patients better manage the risks of cardiovascular diseases," said Henrik Orum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. "SPC5001 is a testament to the efficiency of our LNA Drug Platform and Drug Discovery Engine as we discovered, optimized and advanced SPC5001 into preclinical development in just 18 months."

The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates for a range of diseases including metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

"In addition to advancing SPC5001 into drug development for the treatment of high cholesterol, we remain on track to begin Phase 2 clinical trials of miravirsen (SPC3649) in patients with Hepatitis C in the second half of this year," said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. "In our internal programs and partnered programs, the versatility and broad utility of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine continues to be critical in developing effective RNA-targeted therapies with high affinity, target specificity and remarkable potency for a range of diseases."

SPC5001 adds to the portfolio of Santaris Pharma A/S drugs in development, including its most advanced c
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... YORK , Sept. 19, 2014  An entire ... forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – ... and legs, causing extreme muscle atrophy, weakness, and foot ... the US and millions worldwide. CMT is a progressive ... of their legs, requiring mobility devices such as leg ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
, , Daniel G. Flowers and Lloyd A. Culp, Ph.D., , , , back to top...
... Inc., 2000 Alfred Nobel Drive,Hercules, CA 94547, ... Capillary sequencing technology has altered the field of genomics, ... process. This high-throughput , platform has become ... achievements as the completion of the Human Genome Project. , ...
... Richard Hastings, Jon Saunders and Alan McCarthy ... Liverpool, Liverpool, UK, , Introduction ... firmly focused on the genotypic analysis of naturally-occurring , ... techniques that enable amplification and sequencing of DNA extracted ...
Cached Biology Technology:Comparison of Commercial Dye Terminator Removal Kits, Rev A 2Comparison of Commercial Dye Terminator Removal Kits, Rev A 3Comparison of Commercial Dye Terminator Removal Kits, Rev A 4Comparison of Commercial Dye Terminator Removal Kits, Rev A 5Monitoring Bacterial Genetic Diversity in a Freshwater Lake Using TTGE and DNA Sequence Analysis 2Monitoring Bacterial Genetic Diversity in a Freshwater Lake Using TTGE and DNA Sequence Analysis 3Monitoring Bacterial Genetic Diversity in a Freshwater Lake Using TTGE and DNA Sequence Analysis 4
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 43rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... Many baffled parents have wondered whether their teenagers would ... have never really quite understood just how an organism ... growth should cease. , Now University of Washington biologists ... fly, have discovered an organ that assesses the size ...
... biochemistry and metabolism of disease-causing organisms. The new ... than the 4 traditional Kingdoms. , Here ... causing mortality in AIDS patients and immunocompromised individuals, ... a different treatment regimen is needed. 2) Phytophtora, ...
... grows in the soil of potato fields can -- in ... powerful pesticide used for killing worms on potatoes, researchers have ... for the environment because University of North Carolina at Chapel ... weren't there, it would take 10,000 years for just half ...
Cached Biology News:Researchers find gland that tells fruit flies when to stop growing 2Researchers find gland that tells fruit flies when to stop growing 3New classification of eukaryotes has implications for AIDS treatment, agriculture and beyond 2New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 2New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 3
... tissue microarrays are derived from frozen embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... slides. Sections are large (3-5mm in diameter) ...
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7microns ... large (3-5mm in diameter) in comparison to ...
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
... Precision-designed for Optimal Microdissection , ... enable the precise and rapid extraction of ... and cytology samples with Laser Capture Microdissection., ... for Downstream Molecular Analysis , All CapSure ...
Biology Products: